tradingkey.logo

Moderna Inc

MRNA
41.010USD
+0.140+0.34%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
16.03BValor de mercado
PerdaP/L TTM

Mais detalhes de Moderna Inc Empresa

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Informações de Moderna Inc

Código da empresaMRNA
Nome da EmpresaModerna Inc
Data de listagemDec 07, 2018
CEOBancel (Stephane)
Número de funcionários5800
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 07
Endereço325 Binney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone16177146500
Sitehttps://www.modernatx.com/
Código da empresaMRNA
Data de listagemDec 07, 2018
CEOBancel (Stephane)

Executivos da empresa Moderna Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+336.00%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
53.23K
+24493.00%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
43.87K
+672.00%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Francois Nader, M.D.
Dr. Francois Nader, M.D.
Independent Director
Independent Director
--
--
Ms. Tracey Franklin
Ms. Tracey Franklin
Chief People and Digital Technology Officer
Chief People and Digital Technology Officer
--
--
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
Ms. Kate Cronin
Ms. Kate Cronin
Chief Brand Officer
Chief Brand Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+336.00%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
53.23K
+24493.00%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
43.87K
+672.00%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
782.00M
80.37%
Rest of the World
175.00M
17.99%
Europe
16.00M
1.64%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: qui, 5 de fev
Atualizado em: qui, 5 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.62%
Baillie Gifford & Co.
5.27%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
Outro
70.95%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.62%
Baillie Gifford & Co.
5.27%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
Outro
70.95%
Tipos de investidores
Investidores
Proporção
Investment Advisor
43.38%
Investment Advisor/Hedge Fund
14.01%
Hedge Fund
9.99%
Corporation
4.63%
Research Firm
4.27%
Individual Investor
2.73%
Bank and Trust
1.88%
Venture Capital
1.20%
Pension Fund
1.04%
Outro
16.88%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
1864
297.63M
76.18%
-17.74M
2025Q3
1925
289.85M
74.21%
-20.82M
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
41.10M
10.52%
-518.17K
-1.24%
Sep 30, 2025
Baillie Gifford & Co.
21.85M
5.59%
-247.46K
-1.12%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
20.00M
5.12%
+358.11K
+1.82%
Sep 30, 2025
State Street Investment Management (US)
17.11M
4.38%
-162.04K
-0.94%
Sep 30, 2025
Two Sigma Investments, LP
14.30M
3.66%
-472.03K
-3.19%
Sep 30, 2025
Fidelity Management & Research Company LLC
12.28M
3.14%
-7.18M
-36.87%
Sep 30, 2025
Geode Capital Management, L.L.C.
9.25M
2.37%
+372.07K
+4.19%
Sep 30, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.36%
--
--
Sep 30, 2025
Theleme Partners LLP
8.07M
2.07%
+200.00K
+2.54%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
3.72%
Global X Genomics & Biotechnology ETF
3.52%
First Trust NYSE Arca Biotechnology Index Fund
3.4%
Langar Global HealthTech ETF
3.2%
WisdomTree BioRevolution Fund
2.72%
State Street SPDR S&P Biotech ETF
2.19%
VanEck Biotech ETF
1.82%
Invesco S&P 500 Equal Weight Health Care ETF
1.82%
iShares Health Innovation Active ETF
1.72%
ROBO Global Healthcare Technology & Innovation ETF
1.6%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção3.72%
Global X Genomics & Biotechnology ETF
Proporção3.52%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.4%
Langar Global HealthTech ETF
Proporção3.2%
WisdomTree BioRevolution Fund
Proporção2.72%
State Street SPDR S&P Biotech ETF
Proporção2.19%
VanEck Biotech ETF
Proporção1.82%
Invesco S&P 500 Equal Weight Health Care ETF
Proporção1.82%
iShares Health Innovation Active ETF
Proporção1.72%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.6%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI